ING5 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population originating from the A-549 lung adenocarcinoma cell line. This product consists of a heterogeneous mixture of cells with targeted disruption of the ING5 gene, creating a polyclonal loss-of-function model that retains population diversity and reduces clone-specific artifacts. The gene editing leverages CRISPR/Cas9 technology to ablate ING5 protein expression, enabling robust functional studies of this tumor suppressor in an epithelial cancer context.
The parental A-549 cell line is a widely used human lung adenocarcinoma model, originally isolated from a 58-year-old Caucasian male. These adherent epithelial cells exhibit characteristics of alveolar type II pneumocytes and are frequently employed to investigate lung adenocarcinoma biology, including oncogenic signaling, drug responses, and the molecular underpinnings of epithelial malignancies. Their well-characterized genomic background and experimental tractability make them an ideal host for gene editing to dissect oncogenic pathways and tumor suppressor mechanisms.
ING5 functions as a nuclear tumor suppressor and chromatin remodeling factor within the p53 signaling axis. It acts as a cofactor to enhance p53-mediated transcriptional activation. Upstream, ING5 is regulated by DNA damage signals and E2F1 transcription factor. Upon activation, ING5 associates with histone acetyltransferase complexes (p300/CBP, TRRAP, TIP60) and the mSin3a/HDAC deacetylase complex to modulate chromatin at target promoters. This facilitates p53-dependent expression of key effectors: CDKN1A (p21), BAX, and PUMA, promoting cell cycle arrest and apoptosis in response to genotoxic stress.
In the A-549 background, which maintains functional p53 signaling, ING5 disruption is predicted to impair p53-dependent transcriptional programs, altering proliferation and survival. This model is valuable for dissecting ING5’s role in p53-mediated tumor suppression in lung adenocarcinoma, where p53 pathway dysregulation is frequent. Comparisons with parental controls allow investigation of ING5 functions in senescence, DNA repair, and apoptotic sensitivity, while the polyclonal format permits assessment of phenotypic heterogeneity. Such analyses are critical for understanding how ING5 loss contributes to lung carcinogenesis and therapeutic resistance.
The ING5 Knockout A-549 Polyclonal Cells support diverse applications in tumor suppressor and chromatin biology research. Typical assays include western blotting for ING5 and p53 targets, ChIP-qPCR for histone modifications, flow cytometry-based apoptosis and cell cycle analyses, and proliferation assays. These cells also enable RNA-seq profiling to map transcriptional changes upon ING5 loss, and drug sensitivity screens to evaluate chemotherapeutic responses in a lung cancer context. For additional information, please contact Ascent Research.
